City of Hope

For prostate cancer awareness month, Bamidele A. Adesunloye, MD, MS, and Evan Pisick, MD, discussed recent changes and new developments that have been added to the treatment landscape.

The push for more screening of patients with a history of smoking is providing oncologists the ability to catch small cell lung cancers earlier and potentially change the prognosis of the disease.

In an interview with Targeted Oncology, Jeffrey R. Schriber, MD, highlighted some of the most recent updates in the field of multiple myeloma, and discussed emerging therapies that show promise.

For Leukemia Awareness Month, Salman Fazal, MD, and Tibor Kovacsovics, MD, discussed the importance of biomarker testing and targeting in diagnosis, prognosis, and treatment of acute myeloid leukemia.

In an interview with Targeted Oncology, Ruchi Garg, MD, discussed the evolution of the treatment landscape for patients with endometrial cancer and what trials to watch out for in the future.

RefleXion X1 is now being used at City of Hope Comprehensive Cancer Center.

Ruchi Garg, MD, discusses several important ongoing studies of targeted therapies in patients with recurrent endometrial cancer.

In an interview with Targeted Oncology, Barbara Buttin, MD, discussed important ovarian cancer research for which results were presented during the 2023 ASCO Annual Meeting.

Sagun Shrestha, MD, discusses new trials that are exploring anti PD-1 therapy in the first-line setting for patients with small cell lung cancer.

In an interview with Targeted Oncology™, Patricia Rich, MD, discussed the data presented at ASCO 2023 and other recent trials that she found most exciting and important to the field of NSCLC treatment.

In an interview with Targeted Oncology, Sagun Shrestha, MD, evaluated new developments and clinical trials for patients with extensive-stage small cell lung cancer.

For Sarcoma Awareness Month, Lisa B. Ercolano, MD, and Mark Agulnik, MD, discussed the importance of understanding the genomics of sarcomas and how molecular testing can be useful in this space.

Sagun Shrestha, MD, discusses how the addition of atezolizumab and durvalumab to treatment options for patients with extensive stage small cell lung cancer has impacted the field for the better.

Ruchi Garg, MD, discusses the option of immunotherapy for the treatment of endometrial cancer.

The pan-tumor indication for immunotherapy in patients with mismatch repair deficient/microsatellite instability-high cancers has offered new treatment options and emphasized the importance of biomarker testing.

The National Comprehensive Cancer Network has updated its guidelines to include the recently approved T-cell engaging bispecific antibody epcoritamab for B-cell lymphomas.

In season 4, episode 8 of Targeted Talks, Ruchi Garg, MD, discusses treatment approaches for endometrial cancer now and in the near future.

In an interview with Targeted Oncology, Soyoung Park, MD, discusses the criteria used for determining transplant eligibility and choosing between the different types of transplants for patients with cancer.

Ruchi Garg, MD, discusses current treatment options and strategies being utilized for patients with endometrial cancer.

At the second planned interim analysis of the phase 3 SWOG S1826, the primary progression-free survival end point crossed the protocol-specified statistical boundary.

In an interview with Targeted Oncology, Narissa Nonzee, PhD, discussed a study which focused on increasing colorectal screening rates among patients in ethnic minority communities.

Tanya Dorff, MD, discusses the main findings from a phase 1 study of patients with metastatic castration-resistant prostate cancer.

Retrospective research suggests that low skeletal muscle mass at baseline may negatively impact outcomes in patients receiving chimeric antigen receptor T-cell therapy.

Oncologists are seeing early onset colorectal cancer more frequently, according to Jalal S. Baig, MD, medical oncologist at City of Hope Chicago.

In an interview with Targeted Oncology, Tycel Phillips, MD, discussed what led to the FDA approval of subcutaneous epcoritamab for patients with relapsed/refractory diffuse large B-cell lymphoma and how it adds to the current treatment landscape.

Tycel Phillips, MD, discusses the impact of the recent approval of subcutaneous epcoritamab for the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma after 2 or more lines of systemic therapy.

Jeffrey R. Schriber, MD, FRCP, discusses some of the available treatment options for patients with multiple myeloma and how the treatment landscape has evolved over time.

In an interview with Targeted Oncology for World Ovarian Cancer Day, Natalie Godbee, DO, discussed the current state of treatment for advanced ovarian cancer and how oncologists can get the best outcomes for their patients.

Artificial intelligence and machine learning dramatically alter how medicine is practiced, and cancer detection is no exception, according to Toufic Kachaamy, MD of City of Hope Phoenix.

Branding move and leadership additions part of effort to deliver “one City of Hope” experience to patients across national clinical network.